FDA notified healthcare professionals and the public that on October 25, 2011, Eli Lilly and Company announced a worldwide voluntary market withdrawal of Xigris [drotrecogin alfa (activated)]. In a recently completed clinical trial (PROWESS-SHOCK trial), Xigris failed to show a survival benefit. Xigris failed to show a survival benefit for patients with severe sepsis and […]

Continue reading about Eli Lilly Faces Up to Xigris Truth: Drug Does Not Work